FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy

Inbal Rachmin, Eden Amsalem, Eliahu Golomb, Ronen Beeri, Dan Gilon, Pengfei Fang, Hovav Nechushtan, Gillian Kay, Min Guo, Peter Li Yiqing, Roger S.Y. Foo*, David E. Fisher, Ehud Razin, Sagi Tshori

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background Congestive heart failure (CHF) is a significant health care burden in developed countries. However, the molecular events leading from cardiac hypertrophy to CHF are unclear and preventive therapeutic approaches are limited. We have previously described that microphthalmia-associated transcription factor (MITF) is a key regulator of cardiac hypertrophy, but its cardiac targets are still uncharacterized. Methods and results Gene array analysis of hearts from MITF-mutated mice indicated that ErbB2 interacting protein (Erbin) is a candidate target gene for MITF. We have recently demonstrated that Erbin is decreased in human heart failure and plays a role as a negative modulator of pathological cardiac hypertrophy. Here we show that Erbin expression is regulated by MITF. Under basal conditions MITF activates Erbin expression by direct binding to its promoter. However, under β-adrenergic stimulation Erbin expression is decreased only in wild type mice, but not in MITF-mutated mice. Yeast two-hybrid screening, using MITF as bait, identified an interaction with the cardiac-predominant four-and-a-half LIM domain protein 2 (FHL2), which was confirmed by co-immunoprecipitation in both mouse and human hearts. Upon β-adrenergic stimulation, FHL2 and MITF bind Erbin promoter as a complex and repress MITF-directed Erbin expression. Overexpression of FHL2 alone had no effect on Erbin expression, but in the presence of MITF, Erbin expression was decreased. FHL2-MITF association was also increased in biopsies of heart failure patients. Conclusion MITF unexpectedly regulates both the activation and the repression of Erbin expression. This ligand mediated fine tuning of its gene expression could be an important mechanism in the process of cardiac hypertrophy and heart failure.

Original languageAmerican English
Pages (from-to)85-94
Number of pages10
JournalInternational Journal of Cardiology
Volume195
DOIs
StatePublished - 22 Jul 2015

Bibliographical note

Funding Information:
This research was supported by the Israel Science Foundation [ 1925/12 to S.T and 115/2013 to E.R.], the United States Binational Science Foundation [ 2007220 to E.R. and D.E.F.]; the National Research Foundation of Singapore [ HUJ-CREATE to E.R.], by the NIH [ R01 AR043369-18 and P01 CA163222 to D.E.F], and by a grant from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation [to D.E.F.].

Publisher Copyright:
© 2015 Elsevier Ireland Ltd. All rights reserved.

Keywords

  • Activator
  • Erbin
  • FHL2
  • Gene regulation
  • MITF
  • Repressor

Fingerprint

Dive into the research topics of 'FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy'. Together they form a unique fingerprint.

Cite this